3.02
+1.00%
Close of 9 Nov 2026, in CNY
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About HARBIN GLORIA PHARMACEUTICALS Co
Its shares trade on Shenzhen under the ticker 002437.SZ. It has been listed since 23 June 2010. In the fiscal year to 31 December 2025, it reported revenue of CN¥2.14bn and net income of CN¥376.9m. At that date it held total assets of CN¥3.13bn and shareholders' equity of CN¥2.29bn.
Harbin Gloria Pharmaceuticals Co., Ltd. engages in the research, development, production, and sale of medicines. The company is headquartered in Beijing, Beijing. The company went IPO on 2010-06-23. The firm's products include cardiovascular and cerebrovascular drugs, orthopedic drugs, nutritional drugs, anti-infective drugs, immune-enhancing drugs, diabetes drugs, antineoplastic drugs and electrolytes drugs. The firm is also engaged in the agency, research and development of pharmaceuticals, the provision of clinical services and financial investment business. The firm distributes its products within domestic market and to overseas markets.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 23 Jun 2010
- Employees
- 3,507
- Website
- gloria.cc ↗
Leadership
Pay as last reported
- Ms. Zhenyu ShenChairman of the Board, since 2025
- Mr. Leifeng GuoFinance Director, General Manager, Director, since 2014
- Ms. Yueyin LiuDeputy General Manager, Secretary of the Board, Director, since 2017
- Mr. Kang ZhouDeputy General Manager, Director, since 2018
- Mr. Runbao LiDeputy General Manager
- Mr. Xiaohang WangDeputy General Manager
- Mr. Jin HuDirector, since 2022
- Mr. Yi ChenIndependent Director
- Ms. Lida WangIndependent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Harbin Gloria Pharmaceuticals employs 3,507 full-time employees in Beijing.
- The company produces cardiovascular and cerebrovascular drugs for domestic and overseas markets.
- Harbin Gloria offers a diverse range of pharmaceutical products including diabetes and antineoplastic drugs.
Weaknesses
- The company's products include orthopedic and immune-enhancing drugs with limited market share.
- Harbin Gloria's financial investment business lacks detailed market analysis.
- The firm's clinical services are not widely recognized in the industry.
Opportunities
- Harbin Gloria can expand its nutritional drug segment in the domestic market.
- The company has potential to grow in the overseas market for electrolyte drugs.
- Harbin Gloria's anti-infective drugs could benefit from increased global demand.
Threats
- The domestic pharmaceutical market faces intense competition from established players.
- Overseas markets present challenges due to regulatory differences and tariffs.
- Harbin Gloria's financial investment business is vulnerable to economic downturns.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.